Indication intelligence, analysis and sector perception

Higher to mixed open expected; RegMed sector, share pricing is defined by its contradictions

May 17, 2016 6:37am

However, the way forward cannot be found in the practices of the past

Company mentioned: BLUE,

Where are today’s markets going? Don’t miss access to the upcoming morning’s actionable information.

Subscription sign-up … http://www.regmedinvestors.com/create-account

I say today what others won't, so you can do what others can't; whether information or intelligence is good, bad or somewhere in between – it defines the who, when, where, which and what of it …

Dow futures are UP +0.14% and NASDAQ futures are UP +0.21 %

Stock futures struggled for direction as investors assess a faded rally in oil prices and wait for key inflation data

European markets traded higher following the lead set by markets in Asia, which mostly traded higher.

Most Asian markets advanced as energy plays rallied after rising oil prices spurred a banner session.

Data docket: Inflation numbers are the story of the day, with the April consumer price index for April due out at 8:30 a.m. ET.

The stem, cell and gene therapy regenerative medicine (SCGT&RM) sector closed POSITIVE on Monday, NEGATIVE on Friday, Thursday, Wednesday and last Tuesday.

The stem, cell and gene therapy regenerative medicine sector’s record after the last 5 days (of 43 covered companies):

Monday closed POSITIVE with 12 decliners, 27 advancers and 4 flats;
Friday closed NEGATIVE with 22 decliners, 15 advancers and 6 flats;
Thursday closed NEGATIVE with 36 decliners, 5 advancers and 2 flats;
Wednesday closed NEGATIVE with 30 decliners, 11 advancers and 2 flats;
Last, Tuesday closed NEGATIVE with22 decliners, 18 advancers and 3 flats;

A reminder from Monday’s closing post, “The SCGT&RM sector has taken many twists and turns as it meanders up a day and down another, then up for a day only to turn lower.”

Watching the recent trading ranges and volume highlights lowered thresholds of share pricing as the SCGT&RM sector attempts to rally in the coming week.

Risk factors posts the financial results/earnings have declined as most of our sector companies have declared their operating results, development initiatives and trial advancements.

However, why should we like the micro-caps – their share pricing is constantly being crushed as financing their future is all about discounted value, dilution to stakeholders and checkered by over-hanging warrants.

I just can’t make any long-term bets, since I don't believe it's a good risk/reward on current value and platform propositions.

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades? Watch, wait and listen list:

The iShares Nasdaq Biotechnology (IBB) closed Monday UP +3.06% and is DOWN -0.26% in Tuesday’s pre-market;

The SPDR S&P Biotech ETF (XBI) closed Monday up +4.50% and is DOWN -0.30% in Tuesday’s pre-market;

NASDAQ Biotechnology (NBI) closed up Monday +3%;

The Health Care Select Sector SPDR ETF (XLV) closed Monday up +1.36% and is UP +0.04% in Tuesday’s pre-market;

The iShares Russell 2000 (IWM) closed Monday up +1.27% and is UP +0.33% in Tuesday’s pre-market.

Companies in the spotlight;

bluebird bio (BLUE) closed UP +$0.27 to $38.73. After a week of swings, Friday’s $38.46, Thursday’s $36.20, Wednesday’s $38.62, Tuesday’s $40.80 and last Monday’s $41.05 – the range is anyone’s question. The after-market indication is -$0.10 – SELL;

Opinions expressed are those of the author and are subject to change, and are not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.